Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Moderate Buy" from Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.00.

A number of research firms have recently weighed in on AMLX. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Mizuho upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $3.00 to $7.00 in a research report on Monday, April 7th.

Insider Activity

In related news, CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $74,570.30. Following the sale, the chief executive officer now directly owns 3,355,280 shares of the company's stock, valued at approximately $11,642,821.60. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at $37,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 64,509 shares of company stock worth $222,586 in the last quarter. 11.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after acquiring an additional 4,883 shares during the last quarter. Valeo Financial Advisors LLC purchased a new position in shares of Amylyx Pharmaceuticals in the first quarter worth $35,000. Fox Run Management L.L.C. purchased a new position in shares of Amylyx Pharmaceuticals in the fourth quarter worth $45,000. Alpine Global Management LLC bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at $45,000. Finally, RPO LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Stock Up 4.3 %

Shares of NASDAQ AMLX traded up $0.21 during trading hours on Friday, reaching $5.11. 1,042,067 shares of the stock traded hands, compared to its average volume of 1,238,870. The company's 50-day simple moving average is $3.79 and its two-hundred day simple moving average is $4.19. The company has a market capitalization of $452.76 million, a P/E ratio of -1.34 and a beta of -0.53. Amylyx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. As a group, sell-side analysts forecast that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.